Intellia Therapeutics (NTLA) PT Raised to $85 at Chardan Capital Markets

Chardan Capital Markets analyst Geulah Livshits raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $85.00 (from $57.50) while maintaining a Buy rating.

The analyst commented, "After a strong 4Q20, we see scope for 2021 performance on (1) anticipated guidance around initial NTLA-2001 data in hATTR-PN, (2) 2 IND filings (or equivalent) in HAE and AML, (3) visibility on the company's allogeneic ex vivo strategy, and (4) pipeline expansion. As discussed in our 11 January 2021 preview, Intellia's initiation of dosing the 1st systemic CRISPR therapy was an important milestone for the space and to us, a signal of regulators' growing comfort with in vivo gene editing. We now update our model to reflect Intellia's progress towards the clinic as well as growing validation for gene editing platforms more broadly, based on factors initially outlined in our Chardan Gene Editing Framework"

You May Also Be Interested In

• Brewin Dolphin Holdings Plc. (BRW:LN) (BDNHF) PT Raised to GBP3.90 at Berenberg
• Osisko Gold Royalties Ltd. (OR:CN) (OR) PT Raised to Cdn$23 at Stifel Canada
• Dundee Precious Metals (DPM:CN) (DPMLF) PT Raised to Cdn$13.25 at Stifel Canada